Enveric & MagicMed: Combining Drug Discovery with Clinical Expertise
September 9, 2021
Ryan Allway September 9th, 2021 Psychedelics, Top News Enveric Biosciences Inc.’s (NASDAQ: ENVB) focus has been on discovering and developing cannabinoid-based therapeutics for patients suffering from the side effects of cancer treatments. With the acquisition of MagicMed Industries, the company also sees an opportunity in cancer-related distress from anxiety,... Read more
Mindset Pharma Selects Treatment-Resistant Depression and End of Life Cancer Angst as Indications for MSP-1014, its Novel Psilocybin-Inspired Clinical Candidate
September 9, 2021
Ryan Allway September 9th, 2021 Psychedelics TORONTO, Sept. 09, 2021 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs,... Read more
Novamind Uplists to OTCQB Venture Market
September 9, 2021
Ryan Allway September 9th, 2021 Psychedelics TORONTO, ON / ACCESSWIRE / September 9, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, is pleased to announce that, effective today, its common shares have been approved for trading under the ticker symbol “NVMDF”... Read more
Algernon Pharmaceuticals Confirms DMT Increased Growth of Neurons by 40% in Preclinical Study at Sub Hallucinogenic Dose
September 7, 2021
VANCOUVER, British Columbia, Sept. 07, 2021 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it has confirmed in its own preclinical study, that AP-188 (“N,N-Dimethyltryptamine or “DMT”), increased the growth... Read more
Filament Health Shares to Commence Trading on the OTC Market
September 7, 2021
VANCOUVER, BC, Sept. 7, 2021 /CNW/ – Filament Health Corp. (NEO: FH) (OTC Pink: FLHLF) (“Filament” or the “Company”), an exclusively-natural psychedelic drug discovery company, today announced that it received notification from the Financial Regulatory Authority (“FINRA”) that its shares are qualified to commence trading on the OTC Pink Market (the... Read more
VANCOUVER, British Columbia, Sept. 01, 2021 (GLOBE NEWSWIRE) — KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0) , a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce that it has reached a commercial... Read more
Ryan Allway August 30th, 2021 Psychedelics, Top News Integrated Rehab and Performance Re-Branded as IRP Health to Better Reflect its Planned Evolution into a Multidisciplinary Business VANCOUVER, British Columbia, Aug. 30, 2021 (GLOBE NEWSWIRE) — KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0) , a... Read more
Psychedelic Experience: Treating the Trip that Never Ends
August 30, 2021
Robin Lefferts August 30th, 2021 Exclusive, News, Psychedelics, Top News Psychedelics, including ketamine, psilocybin, and LSD, are gaining traction in the mental health industry as they have been found to be potentially beneficial for conditions ranging from depression to anxiety to PTSD to alcoholism. As psychedelics are entering the... Read more
Delic Announces Medical Advisory Board, Demonstrates Psychedelic Wellness Company’s Commitment to Science
August 26, 2021
Ryan Allway August 26th, 2021 Psychedelics Board Includes Diverse Medical Professionals: Neuroscientist, Anesthesiologist, Addiction Psychiatrist, Interventional Pain Physician and Others to Serve as Thought Leaders and Advisors for Delic Subsidiaries VANCOUVER, BC, Aug. 26, 2021 /PRNewswire/ – Delic Holdings Corp (“Delic” or the “Company“) (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform today... Read more
NeonMind Announces DTC Eligibility
August 25, 2021
Ryan Allway August 25th, 2021 Psychedelics VANCOUVER, BC / ACCESSWIRE / August 25, 2021 / NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBF)(FFE:6UF) (“NeonMind” or the “Company”), an integrated drug development and wellness company focused on the potential therapeutic uses of psilocybin for treating obesity and weight management conditions, announced today that its common shares... Read more
